Related Experiment Video
Updated: May 30, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de
1Hôpital Cochin Assistance Publique des Hôpitaux de Paris (AP-HP), Paris V, France. sophie.park@cch.aphp.fr
Abstract:
We evaluated the prognostic value of serum ferritin (SF) level at diagnosis in 318 newly diagnosed IPSS low and int 1 (lower) risk MDS patients included in the French MDS registry, who did not require RBC transfusions and had baseline SF level determination. Increased baseline SF level (>300 ng/ml) was correlated with male gender, more pronounced anaemia, and diagnosis of RARS but had no negative impact on progression to AML or survival.
Insights
Serum ferritin levels at diagnosis did not predict acute myeloid leukemia (AML) progression or survival in lower-risk myelodysplastic syndromes (MDS) patients. Higher ferritin was linked to male gender, anemia, and RARS subtype.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Prognostic factors are crucial for managing lower-risk MDS.
- Serum ferritin (SF) is increasingly recognized as a potential biomarker.
Purpose of the Study:
- To evaluate the prognostic significance of baseline serum ferritin (SF) levels in lower-risk MDS patients.
- To determine if SF levels predict progression to acute myeloid leukemia (AML) or impact survival.
Main Methods:
- Retrospective analysis of 318 lower-risk MDS patients from the French MDS registry.
- Inclusion criteria: newly diagnosed, no red blood cell (RBC) transfusions, baseline SF level determination.
- Statistical correlation analysis between SF levels and clinical parameters, AML progression, and survival.
Main Results:
- Increased baseline SF (>300 ng/ml) correlated with male gender, more pronounced anemia, and diagnosis of RARS.
- No significant association was found between elevated SF levels and progression to AML.
- Elevated SF levels did not negatively impact patient survival.
Conclusions:
- Baseline serum ferritin level is not a negative prognostic indicator for AML progression or survival in lower-risk MDS.
- SF levels may reflect disease characteristics like anemia and RARS subtype.
- Further research may explore SF's role in iron metabolism and transfusion management in MDS.
